Ovid Therapeutics logo

Ovid Therapeutics (OVID) Q1 2025 Annual Earnings

OVID·Reported May 13, 2025·Before market open

Ovid Therapeutics reported Q1 2025 revenue of $130.0K (-12.2% YoY), beat analyst consensus of $42.5K by $87.5K. Diluted EPS came in at $-0.14 (+17.6% YoY).

Revenue
$130.0Kbeat by $87.5K
Consensus: $42.5K
Diluted EPS
$-0.14met estimate
Consensus: $-0.14
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K/A · 0001628280-25-021055

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Ovid Therapeutics's Q1 2025 earnings report.

Ovid Therapeutics (OVID) reported Q1 2025 earnings on May 13, 2025 before market open.

Ovid Therapeutics reported revenue of $130.0K and diluted EPS of $-0.14 for Q1 2025.

Revenue beat the consensus estimate of $42.5K by $87.5K. EPS beat the consensus estimate of $-0.14 by $0.00.

Compared to the same quarter a year prior, revenue declined 12.2% from $148.0K a year earlier and diluted EPS grew 17.6% from $-0.17.

You can read the 10-K/A periodic report (0001628280-25-021055) directly on SEC EDGAR. The filing index links above go to sec.gov.